Latest News about Compass Pathways
Recent news which mentions Compass Pathways
COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What's Next For This Psychedelics Co?
November 25, 2024
From Benzinga
As Psilocybin Trials Face Delays, Compass Pathways (CMPS) Cuts Workforce To Conserve Cash
October 31, 2024
From Benzinga
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder
September 26, 2024
From Benzinga
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
September 12, 2024
From Benzinga
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
September 05, 2024
From Benzinga
AMA's Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here's What To Expect
January 03, 2024
From Benzinga
The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It
October 12, 2023
Tickers
CMPS
The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It
October 11, 2023
Tickers
CMPS
From Benzinga
How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space
September 22, 2023
Tickers
CMPS
One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
September 18, 2023
From Benzinga
What's Spurring The Growth Of The Psychedelics Market – And How One Company Is Helping As Part Of The Vanguard In This Emerging Field
September 12, 2023
Tickers
CMPS
From Benzinga
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
July 25, 2023
Tickers
CMPS
Can Psychedelics Therapy Be Reimbursed? AMA Releases Details On Coding These Procedures
July 06, 2023
Tickers
CMPS
From Benzinga
Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More
December 13, 2022
From Benzinga
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
December 09, 2022
Tickers
CMPS
From Benzinga
Psychedelics Management Updates: Two Top Companies Appoint New CEOs, Here's What We Know
July 19, 2022
From Benzinga
Patents In The Psychedelics Space: Good Or Bad? It's Complicated, Here's What The Experts Say
May 20, 2022
From Benzinga
From Benzinga
Are Psychedelics Starting to Emerge as Legitimate Therapies?
January 19, 2022
From Stock Gumshoe
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
December 01, 2021
Tickers
CMPS
From Benzinga
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways
November 29, 2021
From Benzinga
PA Psilocybin Bill Could Make The State A Frontrunner In Psychedelic Research, Aiding Vets & First Responders
November 18, 2021
From Benzinga
Tickers
TC
From TechCrunch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.